Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Merit Medical Systems (MMSI)

Merit Medical buys Biolife for $120 million; raises 2025 net sales guidance

Mixed Impact 4 of 5 m&a Written later

Merit Medical completed its merger with Biolife on May 20, 2025, paying about $120 million in cash on hand, and updated its 2025 guidance to include the business. Net sales guidance was raised to $1.480 billion to $1.501 billion from $1.470 billion to $1.490 billion, while the non-GAAP earnings per share range moved to $3.28 to $3.41 from $3.29 to $3.42. Management said the deal will be slightly dilutive to 2025 non-GAAP profitability.

Key points

  • Purchase price of about $120 million, subject to standard adjustments, paid with available cash; merger effective May 20, 2025
  • Biolife projected to contribute $10 million to $11 million of revenue from May 20 to December 31, 2025, after about $15 million in revenue for the twelve months ended December 31, 2024
  • 2025 net sales guidance raised to $1.480 billion to $1.501 billion; non-GAAP EPS guidance $3.28 to $3.41 versus prior $3.29 to $3.42
  • About $7.2 million of non-cash and non-recurring transaction expenses excluded from non-GAAP projections; deal projected to be dilutive to 2025 GAAP net income and EPS

The filing

CompanyMerit Medical Systems (MMSI)
Form8-K, current report
Filed with the SECMay 20, 2025, 4:16 PM ET
Accession number0000856982-25-000035

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 20, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.